Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance in hematological malignancy.

Masao Hirose1, Eiji Hosoi, Shuichi Hamano

  • 1Health Management Center, Naruto University of Education, Tokushima, Japan.

The Journal of Medical Investigation : JMI
|September 19, 2003
PubMed
Summary

Drug resistance in leukemia treatment poses a significant challenge. This review updates research on multidrug resistance (MDR) in hematological malignancies and discusses overcoming MDR for improved clinical treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Gene Expression to Candidate Biomarkers in Ulcerative Colitis: Aquaporin-9 in Neutrophil Extracellular Traps Formation Pathways.

Iranian journal of medical sciences·2026
Same author

A review of fundamentals, challenges, prospects, and emerging trends in hydrate-based desalination.

NPJ clean water·2025
Same author

Pre-weld friction stir processing mitigates hot cracking and strengthens AA6061 fusion welds.

Scientific reports·2025
Same author

Downregulation of MT2-MMP and MT5-MMP in ulcerative colitis serves a diagnostic predictor and potential therapeutic targets.

Molecular biology reports·2025
Same author

Correction: Decellularized skin pretreatment by monophosphoryl lipid A and lactobacillus casei supernatant accelerate skin recellularization.

Molecular biology reports·2025
Same author

An overview of diabetes research achievements during a quarter of a century in Diabetes Research Center.

Journal of diabetes and metabolic disorders·2024

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Current treatments for acute myeloid leukemia and acute lymphocytic leukemia in children and adults show unsatisfactory outcomes.
  • A primary obstacle in leukemia treatment is the emergence of drug resistance, present at diagnosis or as minimal residual disease.
  • Drug resistance mechanisms stem from genetic or epigenetic mutations within the leukemia clone.

Purpose of the Study:

  • To provide an updated review of the biology of multidrug resistance (MDR) in hematological malignancies.
  • To discuss strategies for overcoming MDR in leukemia treatment.
  • To explore the adaptation of updated treatment methods in clinical practice.

Main Methods:

  • Review of existing research on multidrug resistance (MDR) mechanisms in hematological malignancies.

Related Experiment Videos

  • Analysis of drug resistance proteins, including P-gp, MRP, LRP, TAP, ARA, and BCRP.
  • Examination of additional resistance factors like anti-apoptosis, tumor suppressor gene alterations, and clinical risk factors.

    • Main Results:

    • Multidrug resistance (MDR) in leukemia involves drug efflux pumps (e.g., P-gp, MRP, BCRP) and other mechanisms.
    • Anti-apoptosis, genetic/epigenetic mutations, and clinical factors contribute to MDR.
    • Understanding these mechanisms is crucial for developing effective therapies.

    Conclusions:

    • Addressing multidrug resistance (MDR) is essential for improving leukemia treatment efficacy.
    • Novel therapeutic strategies targeting MDR mechanisms are needed.
    • Integrating updated knowledge on MDR into clinical practice can enhance patient outcomes.